<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:media="http://search.yahoo.com/mrss/">
  <channel>
    <title>Artificial intelligence</title>
    <description>
      <![CDATA[]]>
    </description>
    <link>https://www.bioworld.com/rss</link>
    <language>en-us</language>
    <item>
      <title>Financing supports Fathom Therapeutics’ Microcosmos drug design engine</title>
      <description>
        <![CDATA[Fathom Therapeutics, formerly Atommap Corp., has raised $47 million in an oversubscribed series A financing to advance its work using physics-based simulations and AI to model protein motion and interactions at atomic resolution.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730719</guid>
      <pubDate>Tue, 28 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730719-financing-supports-fathom-therapeutics-microcosmos-drug-design-engine</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/finance-dollar-growth.webp?t=1638226495" type="image/png" medium="image" fileSize="416016">
        <media:title type="plain">Hand holding dollar sign</media:title>
      </media:content>
    </item>
    <item>
      <title>AACR 2026: The age of agentic AI in oncology</title>
      <description>
        <![CDATA[New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of experimental compounds fail in clinical trials, underscoring the need for strategies that better capture human biology. Many of these techniques were showcased at the 2026 American Association for Cancer Research (AACR) annual meeting.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730582</guid>
      <pubDate>Thu, 23 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730582-aacr-2026-the-age-of-agentic-ai-in-oncology</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/AI/Abstract-digital-human-face-AI.webp?t=1776955679" type="image/jpeg" medium="image" fileSize="303061">
        <media:title type="plain">Illustration of human face that looks abstract and digital</media:title>
      </media:content>
    </item>
    <item>
      <title>AI opens the way to systematic risk assessment of zoonotic potential of viruses</title>
      <description>
        <![CDATA[Researchers in the U.K. have developed an AI-driven method of identifying viruses in wild animals with the potential to spillover into humans. The technique makes it possible to use the genome sequences of the spike proteins by which viruses enter host cells to assess the potential to infect humans without having to isolate an individual virus and tests its infectivity in the lab.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730553</guid>
      <pubDate>Wed, 22 Apr 2026 11:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730553-ai-opens-the-way-to-systematic-risk-assessment-of-zoonotic-potential-of-viruses</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/Zoonosis-heart-nosed-bats-hanging.webp?t=1776870425" type="image/jpeg" medium="image" fileSize="707396">
        <media:title type="plain">Heart-nosed bats (Cardioderma cor) hanging from the rafters</media:title>
      </media:content>
    </item>
    <item>
      <title>More of everything as Amazon moves into AI-driven drug R&amp;D</title>
      <description>
        <![CDATA[Amazon is extending the reach of its “everything store” into drug R&D with the launch of an artificial intelligence-powered Bio Discovery business. The company has compiled a catalogue of 40-plus foundation models that have been trained on extensive biology datasets and are able to generate and evaluate drug molecules in silico. For now, this covers antibodies only, but it is intended to move into other modalities.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730445</guid>
      <pubDate>Wed, 15 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730445-more-of-everything-as-amazon-moves-into-ai-driven-drug-r-and-d</link>
      <media:content url="https://www.bioworld.com/ext/resources/BW-source/2026/Amazon-Bio-Discovery-4-14.webp?t=1776201314" type="image/jpeg" medium="image" fileSize="234848">
        <media:title type="plain">Amazon Bio Discovery AI-powered application</media:title>
        <media:description type="plain">The Amazon Bio Discovery AI agent helps scientists set up and run AI-powered drug discovery workflows. Credit: www.aboutamazon.com</media:description>
      </media:content>
    </item>
    <item>
      <title>Insilico Medicine and Aska enter gynecological collaboration</title>
      <description>
        <![CDATA[Insilico Medicine Cayman Topco has established a strategic research collaboration with Aska Pharmaceutical Co. Ltd. to identify novel therapeutic targets for challenging gynecological conditions, including endometriosis, uterine fibroids and adenomyosis.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729879</guid>
      <pubDate>Wed, 25 Mar 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729879-insilico-medicine-and-aska-enter-gynecological-collaboration</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/Gynecology-womens-health-female-reproductive-system.webp?t=1774455533" type="image/jpeg" medium="image" fileSize="650388">
        <media:title type="plain">Futuristic medical hologram illustration featuring the female reproductive system</media:title>
      </media:content>
    </item>
    <item>
      <title>Rybodyn raises funding to decode the dark proteome</title>
      <description>
        <![CDATA[Rybodyn Inc. has announced the initial close of a $10 million seed financing to support its work decoding the dark proteome using an AI-powered novel sequencing and discovery platform. The financing will accelerate the company’s transition from foundational discovery into scaled platform execution and progress early-stage programs into IND-enabling studies.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729878</guid>
      <pubDate>Wed, 25 Mar 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729878-rybodyn-raises-funding-to-decode-the-dark-proteome</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/Health-research-body-molecules.webp?t=1743605757" type="image/jpeg" medium="image" fileSize="735256">
        <media:title type="plain">Art concept for medical research</media:title>
      </media:content>
    </item>
    <item>
      <title>PerturbAI emerges from stealth with an atlas full of data</title>
      <description>
        <![CDATA[PerturbAI has emerged from stealth mode with the release of the world’s largest in vivo CRISPR atlas as described in a preprint on <em>Biorxiv</em>. The study profiled over 7.7 million cells from the brains of 74 mice with different cellular knockouts of 1,947 disease-associated genes. The San Francisco-based company’s Perturb-seq platform combines CRISPR perturbations with single nucleus RNA sequencing to look at gene expression.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729875</guid>
      <pubDate>Wed, 25 Mar 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729875-perturbai-emerges-from-stealth-with-an-atlas-full-of-data</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/AI/Artificial-Intelligence-chip-digital-brain.webp?t=1774451411" type="image/jpeg" medium="image" fileSize="1001421">
        <media:title type="plain">Illustration of a computer chip with a brain on it</media:title>
      </media:content>
    </item>
    <item>
      <title>Zelluna, Etcembly partner on AI-enabled T-cell receptor engineering</title>
      <description>
        <![CDATA[Zelluna ASA has established a collaboration with Etcembly Ltd. that will focus on the engineering of high-affinity, tumor-specific T-cell receptors targeting KKLC1.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729415</guid>
      <pubDate>Mon, 09 Mar 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729415-zelluna-etcembly-partner-on-ai-enabled-t-cell-receptor-engineering</link>
    </item>
    <item>
      <title>Digital pathology speeds diagnostics, but tends to take shortcuts to do so</title>
      <description>
        <![CDATA[Computational pathology, which assesses molecular-level features of diseases directly from tissue images (rather than testing the tissue via methods such as staining or sequencing) is making rapid strides.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729148</guid>
      <pubDate>Tue, 03 Mar 2026 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/729148-digital-pathology-speeds-diagnostics-but-tends-to-take-shortcuts-to-do-so</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-source/Computational-Pathology-Fayyaz-Minhas-University-of-Warwick.webp?t=1772555477" type="image/jpeg" medium="image" fileSize="857272">
        <media:title type="plain">Whole slide image illustrating the detection of key histological structures such as glands and cells. </media:title>
        <media:description type="plain">Whole slide image illustrating the detection of key histological structures such as glands and cells. Credit: Fayyaz Minhas/University of Warwick</media:description>
      </media:content>
    </item>
    <item>
      <title>Omnigeniq’s journey from space science to drug design</title>
      <description>
        <![CDATA[A project that started as a bioreactor to assist astronauts in deep space to keep medications safe in a microgravity environment could help pharma companies model how drugs behave in the human body. Omnigeniq unveiled at the J.P. Morgan Healthcare conference the first computer model of a human protein as it exists in the body, confirming that native protein topology can be calculated directly from physics.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729166</guid>
      <pubDate>Wed, 18 Feb 2026 09:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/729166-omnigeniqs-journey-from-space-science-to-drug-design</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/protein-amino-acid-biomolecules-chain.webp?t=1704471407" type="image/jpeg" medium="image" fileSize="434998">
        <media:title type="plain">3D illustration of a chain of amino acid or biomolecules called protein</media:title>
      </media:content>
    </item>
    <item>
      <title>AI meets antibody design: Galux draws $29M series B for drug R&amp;D</title>
      <description>
        <![CDATA[Galux closed a ₩42 billion (US$29 million) series B round Feb. 10, led by Yuanta Investment to bring AI-driven “rational design” to the protein drug development process, already heavily influenced by human engineering.]]>
      </description>
      <guid>http://www.bioworld.com/articles/728800</guid>
      <pubDate>Tue, 10 Feb 2026 09:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/728800-ai-meets-antibody-design-galux-draws-29m-series-b-for-drug-r-and-d</link>
      <media:content url="https://www.bioworld.com/ext/resources/BW-source/2026/Park-Tae-yong-vice-president-and-cofounder-Galux-2-9.webp?t=1770669296" type="image/jpeg" medium="image" fileSize="481724">
        <media:title type="plain">Park Tae-yong, vice president and cofounder, Galux</media:title>
        <media:description type="plain">Park Tae-yong, vice president and cofounder, Galux Inc.</media:description>
      </media:content>
    </item>
    <item>
      <title>Deepmind’s AI model predicts the effect of variants in dark genome</title>
      <description>
        <![CDATA[Google Deepmind is shedding light on the dark genome with its latest AI model, which is trained to decipher the 98% of DNA that does not code for proteins. Alphagenome is designed to predict how variants in the regulatory genome exert their effects on the expression of the genes they control.]]>
      </description>
      <guid>http://www.bioworld.com/articles/728626</guid>
      <pubDate>Tue, 03 Feb 2026 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/728626-deepminds-ai-model-predicts-the-effect-of-variants-in-dark-genome</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/DNA-epigenetics-gene-silencing-digital.webp?t=1742568555" type="image/jpeg" medium="image" fileSize="284545">
        <media:title type="plain">AI-generated illustration of DNA double helix</media:title>
      </media:content>
    </item>
    <item>
      <title>Deepmind’s AI model predicts the effect of variants in dark genome</title>
      <description>
        <![CDATA[Google Deepmind is shedding light on the dark genome with its latest AI model, which is trained to decipher the 98% of DNA that does not code for proteins. Alphagenome is designed to predict how variants in the regulatory genome exert their effects on the expression of the genes they control.]]>
      </description>
      <guid>http://www.bioworld.com/articles/728590</guid>
      <pubDate>Fri, 30 Jan 2026 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/728590-deepminds-ai-model-predicts-the-effect-of-variants-in-dark-genome</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/DNA-epigenetics-gene-silencing-digital.webp?t=1742568555" type="image/jpeg" medium="image" fileSize="284545">
        <media:title type="plain">AI-generated illustration of DNA double helix</media:title>
      </media:content>
    </item>
    <item>
      <title>1,000 experts design a PhD-level exam to test AI capabilities</title>
      <description>
        <![CDATA[How much have AI applications learned, and how can one know their capabilities if they are being evaluated with an exam that is far too easy? In 2024, with the publication of the previous benchmark to measure AI performance, the field debated whether existing assessments would keep pace with the rapid progress of AI.]]>
      </description>
      <guid>http://www.bioworld.com/articles/728432</guid>
      <pubDate>Fri, 30 Jan 2026 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/728432-1-000-experts-design-a-phd-level-exam-to-test-ai-capabilities</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/Artificial-intelligence-human-comparison.webp?t=1769784078" type="image/jpeg" medium="image" fileSize="802733">
        <media:title type="plain">Human intelligence vs. artificial intelligence</media:title>
      </media:content>
    </item>
    <item>
      <title>Deepmind’s AI model predicts the effect of variants in dark genome</title>
      <description>
        <![CDATA[Google Deepmind is shedding light on the dark genome with its latest AI model, which is trained to decipher the 98% of DNA that does not code for proteins. Alphagenome is designed to predict how variants in the regulatory genome exert their effects on the expression of the genes they control.]]>
      </description>
      <guid>http://www.bioworld.com/articles/728412</guid>
      <pubDate>Thu, 29 Jan 2026 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/728412-deepminds-ai-model-predicts-the-effect-of-variants-in-dark-genome</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/DNA-epigenetics-gene-silencing-digital.webp?t=1742568555" type="image/jpeg" medium="image" fileSize="284545">
        <media:title type="plain">AI-generated illustration of DNA double helix</media:title>
      </media:content>
    </item>
    <item>
      <title>AI identifies pregnancies at risk of spontaneous pre-term birth</title>
      <author>greg.kaplan@clarivate.com</author>
      <description>
        <![CDATA[Prenaital ApS    has filed a patent for technology that may identify risks of spontaneous pre-term birth. Spontaneous preterm birth (sPTB) is usually defined as birth occurring before 37 weeks of gestation.&nbsp;<span style=" font-style: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; widows: 2; word-spacing: 0px; display: inline !important; float: none;">The invention relates to a method for predicting potential preterm birth from medical scan data, which may be used in practice by medical professionals for risk analysis and prognosis of potential pathologies.</span>
]]>
      </description>
      <guid>http://www.bioworld.com/articles/728085</guid>
      <pubDate>Fri, 23 Jan 2026 11:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/728085-ai-identifies-pregnancies-at-risk-of-spontaneous-pre-term-birth</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2026/Prenaital-23jan26.webp?t=1769194680" type="image/jpeg" medium="image" fileSize="160383">
        <media:title type="plain">Prenaital CEO and co-founders</media:title>
        <media:description type="plain">From left: Prenaital CEO and co-founder Tanja Danner, DTU professor and co-founder Aasa Feragen and Martin G. Tolsgaard, co-founder and senior physician at Rigshospitalet. Credit: Courtesy DTU. </media:description>
      </media:content>
    </item>
    <item>
      <title>F.Med redefines the future of microsurgical robotics</title>
      <description>
        <![CDATA[Microsurgery is performed to connect small human vessels, but the technical difficulty required to conduct this type of surgery is quite specialized and limits the number of surgeons who can perform microsurgery.]]>
      </description>
      <guid>http://www.bioworld.com/articles/728065</guid>
      <pubDate>Wed, 21 Jan 2026 11:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/728065-fmed-redefines-the-future-of-microsurgical-robotics</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2026/F-med-prototype-mini-robot-21jan26.webp?t=1769029966" type="image/jpeg" medium="image" fileSize="77052">
        <media:title type="plain">F-med prototype mini robot</media:title>
        <media:description type="plain">F.Med’s microsurgery robot prototype. Credit: F.Med</media:description>
      </media:content>
    </item>
    <item>
      <title>Wlanholding CEO says it may be too early to trust AI in health care</title>
      <description>
        <![CDATA[Investors continue to pour capital into AI-driven health care technologies, from drug discovery and diagnostics to personalized medicine and clinical decision-support tools. However, there remain issues with the quality and reliability of the data underpinning these systems, as well as the viability of their business model.]]>
      </description>
      <guid>http://www.bioworld.com/articles/728055</guid>
      <pubDate>Tue, 20 Jan 2026 11:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/728055-wlanholding-ceo-says-it-may-be-too-early-to-trust-ai-in-health-care</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/AI/AI-concept-art.webp?t=1768944356" type="image/jpeg" medium="image" fileSize="1408746">
        <media:title type="plain">Artificial intelligence (AI), machine learning concept art</media:title>
      </media:content>
    </item>
    <item>
      <title>Top and slop: 2026 is shaping up as another big year for AI</title>
      <description>
        <![CDATA[Depending on who you ask, AI will take over the world and save it; or ruin it. Certainly, it is changing it. <em>Science</em> magazine dedicated its first editorial of 2026 to AI. Despite its title – “Resisting AI slop“ – editor-in-chief Holden Thorp gave the sort of nuanced review that is typical of him.]]>
      </description>
      <guid>http://www.bioworld.com/articles/728091</guid>
      <pubDate>Wed, 14 Jan 2026 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/728091-top-and-slop-2026-is-shaping-up-as-another-big-year-for-ai</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/Artificial-Intelligence-in-Healthcare-and-Medical-Technology.webp?t=1767973432" type="image/jpeg" medium="image" fileSize="689816">
        <media:title type="plain">Magnifying glass over AI icon surrounded by health care and medicine icons</media:title>
      </media:content>
    </item>
    <item>
      <title>Illumina Billion Cell Atlas to accelerate AI, drug discovery</title>
      <author>holland.johnson@clarivate.com</author>
      <description>
        <![CDATA[Illumina Inc. presented at the J.P. Morgan 2026 Healthcare Conference on Jan. 13 and introduced what it said is the world's largest genome-wide genetic perturbation dataset, being built to accelerate drug discovery through AI across the pharmaceutical ecosystem. This is a move away from its core focus on DNA sequencing technology.]]>
      </description>
      <guid>http://www.bioworld.com/articles/727810</guid>
      <pubDate>Tue, 13 Jan 2026 11:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/727810-illumina-billion-cell-atlas-to-accelerate-ai-drug-discovery</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2021/09-23-illumina-HQ-building-entrance.webp?t=1632435222" type="image/png" medium="image" fileSize="551655">
        <media:title type="plain">Illumina sign, building</media:title>
        <media:description type="plain">Courtesy of Illumina Inc.</media:description>
      </media:content>
    </item>
    <item>
      <title>Top and slop: 2026 is shaping up as another big year for AI</title>
      <description>
        <![CDATA[Depending on who you ask, AI will take over the world and save it; or ruin it. Certainly, it is changing it. <em>Science</em> magazine dedicated its first editorial of 2026 to AI. Despite its title – “Resisting AI slop“ – editor-in-chief Holden Thorp gave the sort of nuanced review that is typical of him. “Like many tools, AI will allow the scientific community to do more if it picks the right ways to use it,” he wrote. “The community needs to be careful and not be swept up by the hype surrounding every AI product.”]]>
      </description>
      <guid>http://www.bioworld.com/articles/727952</guid>
      <pubDate>Mon, 12 Jan 2026 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/727952-top-and-slop-2026-is-shaping-up-as-another-big-year-for-ai</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/Artificial-Intelligence-in-Healthcare-and-Medical-Technology.webp?t=1767973432" type="image/jpeg" medium="image" fileSize="689816">
        <media:title type="plain">Magnifying glass over AI icon surrounded by health care and medicine icons</media:title>
      </media:content>
    </item>
    <item>
      <title>OpenAI’s GPT Health nudges AI closer to FDA regulatory divide</title>
      <description>
        <![CDATA[Generative AI has largely escaped the U.S. FDA’s regulatory purview up to now, but OpenAI seems poised to create a new source of regulatory angst for the agency. The company unveiled its ChatGPT Health Jan. 7, a large language model that when used professionally could land the company in the FDA’s regulatory crosshairs.]]>
      </description>
      <guid>http://www.bioworld.com/articles/727604</guid>
      <pubDate>Fri, 09 Jan 2026 11:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/727604-openais-gpt-health-nudges-ai-closer-to-fda-regulatory-divide</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/Artificial-Intelligence-in-Healthcare-and-Medical-Technology.webp?t=1767973432" type="image/jpeg" medium="image" fileSize="689816">
        <media:title type="plain">Magnifying glass over AI icon surrounded by health care and medicine icons</media:title>
      </media:content>
    </item>
    <item>
      <title>Top and slop: 2026 is shaping up as another big year for AI</title>
      <description>
        <![CDATA[Depending on who you ask, AI will take over the world and save it; or ruin it. Certainly, it is changing it. <em>Science</em> magazine dedicated its first editorial of 2026 to AI. Despite its title – “Resisting AI slop“ – editor-in-chief Holden Thorp gave the sort of nuanced review that is typical of him. “Like many tools, AI will allow the scientific community to do more if it picks the right ways to use it,” he wrote. “The community needs to be careful and not be swept up by the hype surrounding every AI product.”]]>
      </description>
      <guid>http://www.bioworld.com/articles/727845</guid>
      <pubDate>Fri, 09 Jan 2026 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/727845-top-and-slop-2026-is-shaping-up-as-another-big-year-for-ai</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/Artificial-Intelligence-in-Healthcare-and-Medical-Technology.webp?t=1767973432" type="image/jpeg" medium="image" fileSize="689816">
        <media:title type="plain">Magnifying glass over AI icon surrounded by health care and medicine icons</media:title>
      </media:content>
    </item>
    <item>
      <title>High pressure areas predicted for 2026 medical device landscape</title>
      <description>
        <![CDATA[It doesn’t take a meteorologist to see the storm clouds of uncertainty that will continue to roll in on health care across the globe this year. While the prospects for the medical device industry may be sunnier than for other aspects of health care, some high pressure areas likely will present challenges.]]>
      </description>
      <guid>http://www.bioworld.com/articles/727593</guid>
      <pubDate>Thu, 08 Jan 2026 11:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/727593-high-pressure-areas-predicted-for-2026-medical-device-landscape</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Misc/Yellow-umbrella-in-storm.webp?t=1767737642" type="image/jpeg" medium="image" fileSize="639718">
        <media:title type="plain">Yellow umbrella in a storm</media:title>
      </media:content>
    </item>
    <item>
      <title>New legislation would apply product liability principles to AI</title>
      <description>
        <![CDATA[Software as a service has typically been less susceptible to liability than products, but that may soon come to an end if the AI LEAD Act, sponsored by a bipartisan pair of members of the Senate, gains sufficient traction.]]>
      </description>
      <guid>http://www.bioworld.com/articles/727573</guid>
      <pubDate>Tue, 06 Jan 2026 11:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/727573-new-legislation-would-apply-product-liability-principles-to-ai</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Geographic-regions/US/washington-dc-1624419.webp?t=1588689744" type="image/png" medium="image" fileSize="640104">
        <media:title type="plain">U.S. Capitol building, Washington D.C.</media:title>
      </media:content>
    </item>
    <item>
      <title>Insilico Medicine and Servier collaborate in cancer</title>
      <description>
        <![CDATA[Insilico Medicine Cayman Topco has announced a multiyear research and development collaboration with Laboratoires Servier SAS focused on identifying and developing novel therapeutics for challenging targets in oncology by leveraging Insilico’s proprietary AI platform, Pharma.AI.]]>
      </description>
      <guid>http://www.bioworld.com/articles/727643</guid>
      <pubDate>Mon, 05 Jan 2026 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/727643-insilico-medicine-and-servier-collaborate-in-cancer</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cancer/Cancer-cells-pic.webp?t=1591653278" type="image/png" medium="image" fileSize="432362">
        <media:title type="plain">Digital cancer cells illustration</media:title>
      </media:content>
    </item>
    <item>
      <title>Bayosthiti AI to build India-specific RNA sequencing ecosystem</title>
      <description>
        <![CDATA[Bayosthiti AI Pvt Ltd. aims to make RNA sequencing and AI-based preventive health care affordable and accessible for the Indian market, leveraging intellectual property from its parent company, Biostate AI Inc.]]>
      </description>
      <guid>http://www.bioworld.com/articles/727660</guid>
      <pubDate>Wed, 31 Dec 2025 09:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/727660-bayosthiti-ai-to-build-india-specific-rna-sequencing-ecosystem</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2021/thumb/India-digital-map.webp?t=1632951244" type="image/png" medium="image" fileSize="470231">
        <media:title type="plain">India map on technology concept background</media:title>
      </media:content>
    </item>
    <item>
      <title>FDA’s LDT loss tops regulatory stories of 2025</title>
      <description>
        <![CDATA[The U.S. FDA’s final rule for regulation of lab-developed tests was destined to be controversial at best and exceptionally susceptible to legal challenge according to more than one legal opinion. The inevitable legal challenge succeeded wildly in a decision rendered in district court in March 2025, marking one of the rare instances in which the courts thwarted FDA rulemaking and thus is easily the regulatory story of the year for 2025. Attempts to regulate AI in the U.S. and Europe also dominated the regulatory landscape.]]>
      </description>
      <guid>http://www.bioworld.com/articles/727225</guid>
      <pubDate>Wed, 24 Dec 2025 11:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/727225-fdas-ldt-loss-tops-regulatory-stories-of-2025</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-structure/Aging-digital-hourglass-futuristic.webp?t=1724944821" type="image/jpeg" medium="image" fileSize="320796">
        <media:title type="plain">Hourglass on glowing circuit board, symbolizing time and technology</media:title>
      </media:content>
    </item>
    <item>
      <title>Crescom wins FDA clearance for bone analysis</title>
      <description>
        <![CDATA[Crescom Co. Ltd., an AI musculoskeletal imaging company, gained U.S. FDA 510(k) clearance Dec. 24 for MediAI-BA, its AI-powered pediatric and adolescent bone age analysis software.
Classified as a class II medical device, MediAI-BA evaluates bone age and suggests predicted adult height based on growth plate status assessed by hand and wrist X-ray imaging. Prior clinical trial results demonstrated MediAI-BA had specialist-level accuracy, recording a mean absolute deviation (MAD) of 0.39 years.]]>
      </description>
      <guid>http://www.bioworld.com/articles/727223</guid>
      <pubDate>Wed, 24 Dec 2025 11:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/727223-crescom-wins-fda-clearance-for-bone-analysis</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2025/Crescom-MediAI-BA-24dec25.webp?t=1766601685" type="image/jpeg" medium="image" fileSize="71686">
        <media:title type="plain">Crescom MediAI-BA</media:title>
        <media:description type="plain">Crescom MediAI-BA bone age analysis software. Credit: Crescom</media:description>
      </media:content>
    </item>
    <item>
      <title>Hits’ Hyperlab launches as ‘virtual AI lab’ for new drug discovery</title>
      <description>
        <![CDATA[Things once done in laboratories can now be done with computers and AI, said Kim Woo-youn, CEO and cofounder of Hits Inc. “We live in the age of ‘digital alchemy,’” Kim told <em>BioWorld</em>, describing how AI is shifting some drug discovery processes from physical to virtual spaces.]]>
      </description>
      <guid>http://www.bioworld.com/articles/727277</guid>
      <pubDate>Wed, 17 Dec 2025 09:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/727277-hits-hyperlab-launches-as-virtual-ai-lab-for-new-drug-discovery</link>
      <media:content url="https://www.bioworld.com/ext/resources/BW-source/2025/Kim-Woo-youn-CEO-and-cofounder-Hits-12-15.webp?t=1765911302" type="image/jpeg" medium="image" fileSize="675292">
        <media:title type="plain">Kim Woo-youn, CEO and cofounder, Hits</media:title>
        <media:description type="plain">Kim Woo-youn, CEO and cofounder, Hits</media:description>
      </media:content>
    </item>
  </channel>
</rss>
